Advertisement

Boston Scientific Corp. today announced that one of its coronary stents has been approved for additional treatments of diabetes and heart attacks in the European economic community.

The Natick company said its Promus Element Everolimus-Eluting Coronary Stent System has received CE Mark approval for use in patients with concomitant diabetes mellitus and acute myocardial infarction. The company had received CE Mark approval of the stent for specific indications of diabetes in October 2009.

SOURCE

Advertisement
Advertisement